重磅!仅用3月 FDA批准囊性纤维化突破性疗法(2)
2020-02-21 未知 admin
参考资料:
[1] FDA Approves TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older Who Have at Least One F508del Mutation. Retrieved October 21, 2019, from https://www.businesswire.com/news/home/20191021005792/en
[2] FDA approves new breakthrough therapy for cystic fibrosis. Retrieved October 21, 2019, from https://www.prnewswire.com/news-releases/fda-approves-new-breakthrough-therapy-for-cystic-fibrosis-300942263.html
*声明:本文由入驻新浪医药新闻作者撰写,观点仅代表作者本人,不代表新浪医药新闻立场。▽关注【药明康德】微信公众号
鐑瘝锛